Is There a Relationship Between the Arterial Stiffness and Effectiveness of Acetylsalicylic Acid in Patients with Stable Coronary Artery Disease?

Year 2013, Volume: 16 Issue: 3, 177 - 181, 01.03.2012

Ömer Gedikli Sinan Şahin Caner Karahan Merih Kutlu

https://doi.org/10.5578/kkd.5666

Abstract

Introduction: We aimed to investigate whether arterial stiffness (AS) is associated with effectiveness of acetylsalicylic acid in patients with stable coronary artery disease. Patients and Methods: We enrolled 82 consecutive stable coronary artery disease patients taking at least one week acetylsalicylic acid. AS was evaluated by aortic pulse wave velocity (PWV) and augmentation index (AIx). These parameters were measured with Sphygmo- Cor device. Acetylsalicylic acid effi cacy was evaluated by serum thromboxane B2 (TxB2) level. Results: The mean age was 63 ± 9 years. Aortic PWV was 11.7 ± 2.8 (m/sec) and AIx was 28 ± 9 years (%), in the study group. Serum TxB2 level was 428 ± 1312 (mg/dL). There was no signifi cant correlation between serum TxB2 level and AS parameters. However, total cholesterol (r= 0.21, p= 0.05) and LDL cholesterol (r= 0.25, p= 0.02) levels were signifi cantly correlated with the serum levels of TxB2. Conclusion: The fi ndings of this study suggest that there is no relationship between AS and effi cacy of acetylsalicylic acid in patients with stable coronary artery disease.

Keywords

Arterial stiffness, acetylsalicylic acid, tromboxane B2.

Stabil Koroner Arter Hastalarında “Arterial Stiffness” ile Asetilsalisilik Asidin Etkinliği Arasında Bir İlişki Var mıdır?

Abstract

Giriş: Bu çalışmada stabil koroner arter hastalarında "arterial stiffness (AS)" ile asetilsalisilik asidin etkinliği arasında ilişki olup olmadığı araştırılmıştır. Hastalar ve Yöntem: Çalışmaya stabil koroner arter hastalığı olan (anjiyografi k olarak dokümante edilmiş) ve en az bir hafta boyunca 100 mg asetilsalisilik asit kullanan 82 ardışık hasta alındı. AS'ın değerlendirilmesinde aortik nabız dalga hızı (NDH) ve augmentasyon indeksi (AIx) kullanıldı. Bu parametreler SphygmoCor cihazı ile ölçüldü. Asetilsalisilik asidin etkinliği serum tromboksan (Tx) B2 düzeyleriyle değerlendirildi. Bulgular: Çalışma grubunun yaş ortalaması 63 ± 9 yıl idi. Çalışma grubunda aortik NDH 11.7 ± 2.8 (m/sn) ve AIx 28 ± 9 (%) olarak bulundu. Hastaların serum TxB2 düzeyleri 428 ± 1312 (mg/ dL) idi. Serum TxB2 ile AS parametreleri olan aortik NDH (r= 0.01, p= 0.8) ve AIx (r= 0.1, p= 0.4) arasında anlamlı ilişki saptanmadı. Ancak total kolesterol (r= 0.21, p= 0.05) ve LDL kolesterol (r= 0.25, p= 0.02) düzeyleri ile serum TxB2 düzeyleri arasında anlamlı korelasyon saptandı. Sonuç: Bu çalışmanın bulguları stabil koroner arter hastalarında AS ile asetilsalisilik asidin etkinliği arasında ilişki olmadığını düşündürmektedir.

Keywords

Arterial stiffness, asetilsalisilik asit, tromboksan B2.

References

• Power RF, Hynes BG, Moran D, Yagoub H, Kiernan G, Ruggiero NJ, et al. Modern antiplatelet agents in coronary artery disease. Expert Rev Cardiovasc Ther 2012;10:1261-72.
• Abaci O, Kilickesmez KO. Asetilsalisilik asit resistance: where are we now? Anadolu Kardiyol Derg 2013;13:370-3.
• Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A pro- spective, blinded determination of the natural history of asetilsali- silik asit resistance among stable patients with cardiovascular dis- ease. J Am Coll Cardiol 2003;19:961-5.
• Niccoli G, Giubilato S, Russo E, Spaziani C, Leo A, Porto I, et al. Plasma levels of thromboxane A2 on admission are associated with no-refl ow after primary percutaneous coronary intervention. Eur Heart J 2008;29:1843-50.
• Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. Expert consensus document on arterial stiff- ness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605.
• Tomlinson LA. Methods for assessing arterial stiffness: technical considerations. Curr Opin Nephrol Hypertens 2012;21:655-60.
• Palatini P, Casiglia E, Gąsowski J, Głuszek J, Jankowski P, Narkiewicz K, et al. Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension. Vasc Health and Risk Manag 2011;7:725-39.
• Sakuragi S, Abhayaratna WP. Arterial stiffness: methods of meas- urement, physiologic determinants and prediction of cardiovascu- lar outcomes. Int J Cardiol 2010;138:112-8.
• Yamasaki F, Furuno T, Sato K, Zhang D, Nishinaga M, Sato T, et al. Association between arterial stiffness and platelet activation. J Hum Hypertens 2005;19:527-33.
• Pauca AL, O’Rourke MF, Kon ND. Prospective evaluation of a method for estimating ascending aortic pressure from the radial artery pressure waveform. Hypertension 2001;38:932-7.
• Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The infl uence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000;525:263-70.
• Cooper JN, Evans RW, Mori Brooks M, Fried L, Holmes C, Barinas- Mitchell E, et al. Associations between arterial stiffness and plate- let activation in normotensive overweight and obese young adults. Clin Exp Hypertens 2013 (doi: 10.3109/10641963.2013.789045).
• Mason PJ, Jacobs AK, Freedman JE. Asetilsalisilik asit resistance and atherothrombotic disease. J Am Coll Cardiol 2005;46:986-93.
• Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet cyclooxygenase inhibition by low-dose asetilsalisilik asit is not refl ected consistently by platelet function assays: implications for asetilsalisilik asit “resistance”. J Am Coll Cardiol 2009;53:667-77.
• Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Pali- saitis DA, Diodati JG. A comparison of six major platelet func- tion tests to determine the prevalence of asetilsalisilik asit resist- ance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-8.
• Blann AD, Kuzniatsova N, Lip GY. Vascular and platelet responses to asetilsalisilik asit in patients with coronary artery disease. Eur J Clin Invest 2013;43:91-9.
• Petra D, Bernd E. Low-density lipoproteins supply phospholipid- bound arachidonic acid for platelet eicosanoid production. Am J Physiol Endocrinol Metab 1998;275:777-84.
• Friend M, Vucenık I, Miller M. Research pointers: platelet respon- siveness to asetilsalisilik asit in patients with hiperlipidemia. BMJ 2003;326:82-83.